

**Table 11.6h**  
**Persistency of Discharge Regimen by Follow-up Period, 2004 to 2008**  
**Recipients with Heart Transplants**

	Year of Transplant				
	2004	2005	2006	2007	2008
<b>Discharge Regimen (w/ or w/o Steroid Use)</b>					
<b>CyA+Aza</b>					
At Discharge (N)	84	48	43	30	17
At Discharge (%)	100.0%	100.0%	100.0%	100.0%	100.0%
1 Year PostTx (%)	63.1%	76.7%	74.4%	58.6%	50.7%
2 Years PostTx (%)	41.3%	41.7%	46.5%	25.6%	-
3 Years PostTx (%)	30.0%	30.2%	44.2%	25.6%	-
<b>CyA+MMF</b>					
At Discharge (N)	752	637	612	547	415
At Discharge (%)	100.0%	100.0%	100.0%	100.0%	100.0%
1 Year PostTx (%)	77.9%	81.9%	81.0%	78.8%	73.4%
2 Years PostTx (%)	61.3%	65.4%	66.4%	63.5%	57.6%
3 Years PostTx (%)	52.3%	55.9%	56.5%	51.4%	-
<b>CyA+Siro</b>					
At Discharge (N)	2	2	2	-	2
At Discharge (%)	100.0%	100.0%	100.0%	-	100.0%
1 Year PostTx (%)	50.0%	100.0%	50.0%	-	50.0%
2 Years PostTx (%)	50.0%	0.0%	50.0%	-	0.0%
3 Years PostTx (%)	50.0%	0.0%	50.0%	-	0.0%
<b>Siro+MMF</b>					
At Discharge (N)	24	17	25	7	6
At Discharge (%)	100.0%	100.0%	100.0%	100.0%	100.0%
1 Year PostTx (%)	75.0%	64.7%	87.5%	57.1%	41.7%
2 Years PostTx (%)	58.3%	64.7%	75.0%	57.1%	-
3 Years PostTx (%)	54.2%	47.1%	62.5%	57.1%	-
<b>Tac+Aza</b>					
At Discharge (N)	23	20	27	20	28
At Discharge (%)	100.0%	100.0%	100.0%	100.0%	100.0%
1 Year PostTx (%)	78.3%	60.0%	77.8%	72.2%	63.0%
2 Years PostTx (%)	60.9%	45.0%	59.3%	58.3%	63.0%
3 Years PostTx (%)	47.8%	39.4%	59.3%	58.3%	-
<b>Tac+MMF</b>					
At Discharge (N)	724	941	1,059	1,237	1,357
At Discharge (%)	100.0%	100.0%	100.0%	100.0%	100.0%
1 Year PostTx (%)	83.9%	86.1%	87.6%	86.0%	82.9%
2 Years PostTx (%)	73.5%	75.7%	77.5%	74.2%	69.5%
3 Years PostTx (%)	66.5%	70.6%	70.3%	68.3%	-
<b>Tac+Siro</b>					
At Discharge (N)	19	23	26	7	5
At Discharge (%)	100.0%	100.0%	100.0%	100.0%	100.0%

(Continued)

Source: OPTN/SRTR Data as of October 1, 2010.

Notes:

Regimen change is defined as being on different drug combination at follow-up comparing to discharge, or indication of conflicting regimen (CyA vs. Tac; MMF/MPA vs. Aza; Siro vs. Evero) during follow-up period, or graft failure/death. Addition or deletion of steroids is not considered a regimen change.

Rates are calculated for the most common discharge regimens.

CyA: Cyclosporine; Tac: Tacrolimus; MMF: Include MMF(Mycophenolate Mofetil) and MPA(Mycophenolate Sodium); Aza: Azathioprine; Siro: Sirolimus.

See Technical Notes for further details.

**Table 11.6h (Continued)**  
**Persistency of Discharge Regimen by Follow-up Period, 2004 to 2008**  
**Recipients with Heart Transplants**

	Year of Transplant				
	2004	2005	2006	2007	2008
<b>Discharge Regimen (w/ or w/o Steroid Use)</b>					
Tac+Siro					
1 Year PostTx (%)	55.7%	82.6%	69.2%	85.7%	80.0%
2 Years PostTx (%)	44.6%	69.6%	61.5%	64.3%	80.0%
3 Years PostTx (%)	33.4%	60.9%	61.5%	64.3%	-

Source: OPTN/SRTR Data as of October 1, 2010.

Notes:

Regimen change is defined as being on different drug combination at follow-up comparing to discharge, or indication of conflicting regimen (CyA vs. Tac; MMF/MPA vs. Aza; Siro vs. Evero) during follow-up period, or graft failure/death. Addition or deletion of steroids is not considered a regimen change.

Rates are calculated for the most common discharge regimens.

CyA: Cyclosporine; Tac: Tacrolimus; MMF: Include MMF(Mycophenolate Mofetil) and MPA(Mycophenolate Sodium); Aza: Azathioprine; Siro: Sirolimus.

See Technical Notes for further details.